$10M milestone for Isis Pharma from AstraZeneca for ISIS-ARRx to treat prostate cancer

4 June 2013

USA-based Isis Pharmaceuticals (Nasdaq: ISIS) says that Anglo-Swedish drug major AstraZeneca (LSE: AZN) has added a second development candidate, ISIS-ARRx, to its collaboration, meaning that Isis has earned a $10 million milestone payment associated with this decision.

ISIS-ARRx is an antisense drug designed to treat patients with prostate cancer by inhibiting the production of the androgen receptor (AR). AstraZeneca is planning to develop ISIS-ARRx broadly to treat patients under a variety of settings during the course of prostate cancer treatment, including both as a single agent and in combination therapy.

In 2012, Isis entered into a collaboration with AstraZeneca to discover and develop antisense drugs to treat cancer. With the selection of ISIS-ARRx, Isis has earned $35 million in upfront and milestone payments from AstraZeneca and is eligible for additional milestone payments as the drug progresses in development as well as royalties on sales if ISIS-ARRx is successfully commercialized.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK